Oncolytics Biotech, Inc.

Oncolytics Biotech, Inc. engages in the development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. It offers a non-pathogenic, properietary isolate of the reovirus that induce selective tumor lysis, and promotes an inflamed tumor phenotype through innate and adaptive immune responses. The company was founded by Matthew C. Coffey and Bradley George Thompson on April 2, 1998 and is headquartered in Calgary, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Oncolytics Biotech reports strong earnings and growth opportunities ahead

Oncolytics Biotech's Q4 2022 earnings call highlighted notable progress, strong financials, and promising trial outcomes.
The company faces challenges in trial design and collaboration agreements but is well-positioned for growth.
Opportunities lie in upcoming trial readouts, business development efforts, and expansion into Asian markets.

Oncolytics Biotech progresses in key trials, eyes market impact

Oncolytics Biotech, Inc. demonstrated progress in key trials and financial stability, positioning itself for potential market impact.
Strategic focus on validating data, understanding mechanisms of action, and pursuing efficient registration pathways underscores the company's commitment to innovation.
Challenges in managing trial outcomes and sustaining growth require careful navigation, but opportunities in diversification and market expansion offer avenues for success.
Overall, the company's emphasis on strategic milestones and licensing opportunities signals a proactive approach to maximizing value and market potential.

Oncolytics Biotech reports positive Q2 results and eyes growth opportunities

Oncolytics Biotech's Q2 2023 earnings call highlighted positive progress in clinical trials and strong financial performance.
The company's focus on research and development, business development efforts, and commitment to expansion present growth opportunities.
Challenges include trial execution concerns, complexities in combining treatments, and regulatory pathways that need to be navigated.

Oncolytics Biotech reports positive Q3 results and eyes strategic partnerships

Oncolytics Biotech demonstrated strong performance and promising outcomes in Q3 2023, with pela showing success in clinical trials for pancreatic and colorectal cancers.
While facing challenges in data clarity and market positioning, the company has opportunities to expand treatments, collaborations, and advance regulatory studies.
Overall, the company's financial stability, clinical progress, and strategic partnerships position it well for future growth and advancements in cancer treatments.

Oncolytics Biotech reports robust earnings, eyes oncology expansion in 2024

Oncolytics Biotech, Inc. showcased strong financial performance and progress in becoming a late-stage cancer company.
While facing challenges in research validation and managing operating costs, the company is well-positioned for growth.
Opportunities lie in validating survival benefits, expanding pela's market potential, and advancing strategic objectives in oncology.
Overall, Oncolytics' focus on innovation, financial prudence, and clinical advancements sets a positive trajectory for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Clinical interim data reported earlier today from GOBLET trial's pancreatic cancer cohort show an objective response rate (ORR) nearly triple the average ORR seen in relevant historical control trials Pipeline now provides multiple registration opportunities in breast and pancreatic cancer $32.4 million in cash and cash equivalents as of September 30, 2022 provides projected runway through key milestones to the end of 2023 Management hosting conference call and webcast today at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Nov. 7, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the third quarter ended September 30, 2022.

Oncolytics Biotech® Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

70% objective response rate (ORR; n=10) is nearly triple the average ORR of ~25% reported in historical control trials 1-4 Data suggest pelareorep synergizes with PD-(L)1 inhibitors and standard-of-care chemotherapy in advanced/metastatic pancreatic ductal adenocarcinoma Oncolytics plans to present pancreatic cancer data to regulators to determine the most expeditious path to approval Company management to discuss these results and ongoing efforts to advance pelareorep into registration studies in breast and pancreatic cancer during Q3 earnings call today at 8:30 a.m. ET Updated data from GOBLET's pancreatic cancer cohort to be presented in a poster at the SITC meeting and discussed during a key opinion leader webinar on November 14 th at 10 a.m.

Oncolytics Biotech® Reports Interim Results from Phase 1/2 GOBLET Study Showing a 70% Objective Response Rate in Pancreatic Cancer at the SITC Annual Meeting

Mr. Rigby is the Group Chief Executive Officer of Revolo Biotherapeutics and has three decades of experience in the pharmaceutical and biotechnology industries SAN DIEGO and CALGARY, AB , Sept. 7, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the appointment of Jonathan Rigby to its Board of Directors.

Oncolytics Biotech® Appoints Jonathan Rigby to its Board of Directors

Oncolytics Biotech Inc. (NASDAQ:ONCY ) Q2 2022 Results Conference Call August 11, 2022 8:30 AM ET Company Participants Jon Patton - Director of Investor Relations and Communications Matthew Coffey - President and Chief Executive Officer Kirk Look - Chief Financial Officer Thomas Heineman - Chief Medical Officer Andrew de Guttadauro - President Conference Call Participants Jason Kolber - HC Wainwright Operator Good afternoon, and welcome to Oncolytics Biotech's Second Quarter 2022 Conference Call. All participants are now in listen-only mode.

Oncolytics Biotech Inc. (ONCY) CEO Matthew Coffey on Q2 2022 Results - Earnings Call Transcript

Phase 2 BRACELET-1 trial fully enrolled and advancing towards a randomized data readout that is expected to inform the design of a registrational study in HR+/HER2- breast cancer Achieved success criteria for efficacy in Stage 1 of the GOBLET trial's pancreatic cancer cohort with partial responses in all phase 1b patients Clinical biomarker data show pelareorep remodeling tumor microenvironments to improve prognosis and decrease the risk of recurrence in HR+/HER2- breast cancer patients $33.7 million in cash and cash equivalents provides projected runway into the second half of 2023 and through key clinical readouts in breast and pancreatic cancer Management hosting conference call and webcast today at 8:30 a.m. ET SAN DIEGO and CALGARY, AB , Aug. 11, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the second quarter ended June 30, 2022.

Oncolytics Biotech® Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

Boot Barn Hlds

Canada Goose Holdings

Leap Therapeutics

MEDNAX

Want to try an out-of-the-box approach? Tap Oncolytics Biotech (ONCY), Pediatrix Medical Group Inc (MD), Boot Barn (BOOT), Canada Goose (GOOS) and Leap Therapeutics (LPTX).

Ride on Rising P/E Investing With These 5 Top-Ranked Stocks

Partial responses achieved in all patients in cohort's 1b portion Expansion criteria for pancreatic cancer cohort has been met to allow for additional patient enrollment Data suggest pelareorep synergistically combines with chemotherapy and checkpoint inhibition in a highly challenging indication and are featured in an abstract at the ESMO World Congress on Gastrointestinal Cancer SAN DIEGO and CALGARY, AB , June 28, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that the pancreatic cancer cohort of the multi-indication phase 1/2 GOBLET study has met the efficacy expansion criteria for Stage 1 of the trial. The data from the phase 1b portion of this cohort, which are featured in an abstract accepted for a poster presentation at the European Society for Medical Oncology (ESMO) World Congress on Gastrointestinal Cancer 2022, show a strong efficacy signal as evidenced by all patients achieving a partial response (n = 3).

Oncolytics Biotech® Achieves Success Criteria for Efficacy in the Pancreatic Cancer Cohort of GOBLET

Mr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired by Pfizer Inc. SAN DIEGO and CALGARY, AB , June 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Thursday, June 16, 2022. A total of 40.43% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of Directors

SAN DIEGO, Calif. and CALGARY, AB , May 10, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will participate in a fireside chat at the 2022 RBC Capital Markets Global Healthcare Conference, which is taking place May 17-18, 2022 at the InterContinental New York Barclay in New York, NY.

Oncolytics Biotech® to Participate in a Fireside Chat at the 2022 RBC Capital Markets Global Healthcare Conference

Oncolytics Biotech, Inc. (NASDAQ:ONCY ) Q1 2022 Earnings Conference Call May 5, 2022 5:00 PM ET Corporate Participants Jon Patton - Director, Investor Relations and Communications Matthew Coffey - President and Chief Executive Officer Thomas Heineman - Chief Medical Officer Andrew de Guttadauro - Global Head of Business Development, President, Oncolytics Biotech (U.S.) Inc. Kirk Look - Chief Financial Officer Conference Call Participants John Newman - Canaccord Jason Kolbert - HC Wainwright Operator Good afternoon, and welcome to Oncolytics Biotech's First Quarter 2022 Conference Call. All participants are now in a listen-only mode.

Oncolytics Biotech, Inc. (ONCY) CEO Matthew Coffey on Q1 2022 Results - Earnings Call Transcript

Anticipated Q4 2022 data readout from randomized phase 2 study in breast cancer is on track and expected to inform the design of a registrational trial Clinical biomarker data demonstrates pelareorep's induced improvement in the prognosis of HR+/HER2- breast cancer patients by decreasing their risk of recurrence Preclinical data demonstrating the synergistic anti-cancer activity of pelareorep combined with CAR T cell therapy in solid tumors published in Science Translational Medicine $39.5 million in cash and cash equivalents expected to provide runway through key catalysts and into 2023 Management hosting conference call and webcast today at 5:00 p.m. ET SAN DIEGO, Calif and CALGARY, AB , May 5, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced recent operational highlights and financial results for the first quarter ended March 31, 2022.

Oncolytics Biotech® Reports First Quarter 2022 Financial Results and Recent Operational Highlights

Pelareorep treatment resulted in a favorable Risk of Recurrence Score (ROR-S) in 100% of evaluable patients compared to 55% at baseline in a window-of-opportunity study Statistically significant increases in markers of tumor cell death and T cell activation observed following treatment with pelareorep-based combinations SAN DIEGO and CALGARY, AB , May 4, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Cancer Research today announced new clinical biomarker data demonstrating pelareorep's immunotherapeutic effects, synergy with checkpoint inhibition, and potential to improve the outlook for patients with HR+/HER2- breast cancer. The data, which are featured in a poster presentation at the 2022 European Society for Medical Oncology (ESMO) Breast Cancer Meeting, are from cohorts 1 and 2 of the AWARE-1 window-of-opportunity study in early-stage breast cancer patients.

Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep's Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting

SAN DIEGO, Calif. and CALGARY, AB , May 2, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) and SOLTI-Innovative Cancer Research today announced the acceptance of an abstract for a poster presentation at the upcoming European Society for Medical Oncology Breast Cancer Meeting, which is taking place both online and in-person at hub27 – Messe Berlin in Berlin, Germany from May 3-5, 2022.

Oncolytics Biotech® and SOLTI Announce Upcoming Poster Presentation at the European Society for Medical Oncology Breast Cancer Meeting

SAN DIEGO, Calif. and CALGARY, AB , April 21, 2022 /PRNewswire/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Dr. Matt Coffey, President and Chief Executive Officer, will be presenting a corporate overview at the Bloom Burton & Co. Healthcare Investor Conference, which is taking place May 2-3, 2022 at the Metro Toronto Convention Centre, North Building in Toronto, Ontario.

Oncolytics Biotech® to Present at the Bloom Burton & Co. Healthcare Investor Conference

- Pelareorep-CAR T combination may expand the commercial potential of CAR T cells to solid tumors - Combining CAR T cells with pelareorep prevented antigen escape by creating CAR T cells with dual specificity through a novel mechanism - Loading CAR T cells with pelareorep led to dramatic improvements in their persistence and anti-cancer activity as well as cures in multiple murine solid tumor models SAN DIEGO, Calif. and CALGARY, AB , April 14, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of preclinical data demonstrating the synergistic anti-cancer activity of pelareorep combined with chimeric antigen receptor (CAR) T cell therapy in solid tumors.

Oncolytics Biotech® Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors in Science Translational Medicine

SAN DIEGO, Calif. and CALGARY, AB, April 12, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Thomas Heineman, M.D.

Oncolytics Biotech® to Participate in a Fireside Chat at the Canaccord Genuity Horizons in Oncology Virtual Conference

- Results demonstrate meaningful and durable efficacy signal in a highly challenging indication - A higher dose level of pelareorep led to 50% 24-month median overall survival (mOS) and a patient still alive at 42 months compared to 16.7% mOS at the lower dose - Investigator-sponsored trial confirms pelareorep's favorable safety profile SAN DIEGO and CALGARY, AB , April 8, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced positive long-term survival data from ReoGlio, an investigator-sponsored phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant temozolomide for the treatment of glioblastoma multiforme (GBM). The results, which are the subject of a presentation at the American Association for Cancer Research (AACR) Annual Meeting, show a substantial and durable efficacy signal in newly diagnosed GBM patients and demonstrate the safety and tolerability of the studied treatment combination in this indication.

Oncolytics Biotech® Announces Positive Long-Term Survival Data from Phase 1b Glioblastoma Multiforme Trial at the AACR Annual Meeting

- Pelareorep's immunotherapeutic effects produced progression-free survival of >3 years in a subset of multiple myeloma patients who had failed prior therapy - Results strengthen the clinical dataset demonstrating pelareorep's ability to remodel the tumor microenvironment SAN DIEGO and CALGARY, AB , April 8, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of an electronic poster at the American Association for Cancer Research (AACR) Annual Meeting featuring new clinical biomarker data from a completed investigator-sponsored phase 1b trial of pelareorep and the proteasome inhibitor bortezomib in relapsed/refractory multiple myeloma patients. "The results from this trial provide a powerful example of how pelareorep's immunologic effects trigger a durable clinical benefit in an extremely challenging patient population," said Thomas Heineman, M.D.

Oncolytics Biotech® Presents New Data Demonstrating Durable Clinical Benefit in Relapsed/Refractory Multiple Myeloma Patients at the AACR Annual Meeting

SAN DIEGO, Calif. and CALGARY, AB, April 6, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) is providing a letter to shareholders, included below.

Oncolytics Biotech® Letter to Shareholders - Update on Recent Progress

Independent review identified, no safety concerns in trial's final safety run-in Cohort supported by prior clinical data showing a pelareorep-based combination driving a 90% clinical benefit rate in KRAS-mutated colorectal cancer patients Multi-indication trial being conducted in collaboration with Roche and AIO also includes pancreatic and advanced anal cancer cohorts  SAN DIEGO, Calif. and CALGARY, AB , March 31, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the successful completion of the three-patient safety run-in for the third-line metastatic colorectal cancer (mCRC) cohort of the phase 1/2 GOBLET study, following an independent review by the study's Data Safety Monitoring Board (DSMB).

Oncolytics Biotech® Provides Positive Safety Update on the Third-Line Metastatic Colorectal Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

First two cohorts indicate pelareorep in combination with paclitaxel was well-tolerated with no new safety signals observed to date Trial is designed to satisfy regulatory requirements and accelerate pelareorep's development in large and rapidly growing pharmaceutical markets, including China, Hong Kong, Macau, Taiwan, Singapore, and South Korea Final cohort's dosing regimen is equivalent to Oncolytics' North American phase 2 trial in metastatic breast cancer (BRACELET-1) SAN DIEGO, Calif. and CALGARY, AB , March 24, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that its partner Adlai Nortye has advanced to the third and final dose escalation cohort of the bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer.

Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort

SAN DIEGO and CALGARY, AB, March 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced the publication of preclinical and patient data on pelareorep in the peer-reviewed journal Immunology. The paper, entitled "Oncolytic virus treatment differentially affects the CD56dim and CD56bright NK cell subsets in vivo and regulates a spectrum of human NK cell activity," was published in collaboration with researchers at several prestigious institutions, including the University of Leeds School of Medicine and the Institute of Cancer Research, London.

Oncolytics Biotech® Announces Publication of Preclinical and Patient Data Demonstrating Pelareorep's Stimulation of Natural Killer Cell Anti-Cancer Activity

- Prolonged progression-free survival of >3 years achieved in a subset of relapsed/refractory patients - Treatment-induced increases in tumor-infiltrating anti-cancer immune cells correlated with clinical response SAN DIEGO, Calif. and CALGARY, AB, March 9, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced phase 1b data demonstrating clinical proof-of-concept for pelareorep-proteasome inhibitor combination therapy in multiple myeloma.

Oncolytics Biotech® Announces Phase 1b Data Demonstrating Clinical Proof-of-Concept for Pelareorep-Proteasome Inhibitor Combination in Multiple Myeloma in an Abstract at the AACR Annual Meeting

SAN DIEGO, Calif. and CALGARY, AB, March 9, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced an upcoming poster presentation that will feature long-term follow-up results from ReoGlio, an investigator-sponsored, phase 1b trial evaluating the combination of pelareorep and granulocyte-macrophage colony-stimulating factor (GM-CSF) alongside standard chemoradiotherapy and adjuvant temozolomide for the treatment of glioblastoma multiforme (GBM).

Oncolytics Biotech® Announces Upcoming Poster Presentation at the AACR Annual Meeting

Oncolytics Biotech, Inc. (ONCY) CEO Matthew Coffey on Q4 2021 Results - Earnings Call Transcript

News for Oncolytics Biotech, Inc. Stock (ONCY)